On November 6, GENFLEET-B recorded an Intraday Decline of 6.14% in Regular Trading, with the stock trading at HK$23.08 and turnover of HK$5.46 million.
The latest available market update indicates the stock is pulling back after a sharp prior-session advance that had been driven by several already disclosed catalysts, including new clinical trial approvals for GFH276 combination therapies, an institutional stake increase to 5.05%, and continued share buybacks.
Previously disclosed details showed an institution bought 299,600 shares on October 30 at an average price of HK$23.4445, lifting its long position from 4.96% to 5.05%. Separately, the company disclosed that during October it repurchased 1.1488 million H shares and held them as treasury shares. The company had also announced that multiple innovative combination therapies for oral pan-RAS inhibitor GFH276 received clinical trial clearance in China or filing completion in Australia. No new catalyst was identified at the time of this move.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments